Announcement on the Project of Annual Production of 2 billion Solid Preparations by Peak Pharmaceutical
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: Pro 2018-024
Bond Abbreviation: 13 Spike 02 Bond Code: 122344
Announcement of Zhejiang Jianfeng Group Co., Ltd.
on Jianfeng Pharmaceutical's Annual Production of 2 billion Solid Preparations
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assume individual and joint responsibility for the truthfulness, accuracy and completeness of its contents.
Important Content Note:
l Project Name: 2 billion Pieces of Solid Preparation Project
l Annual Output of Jinxi Production Base of Jianfeng Pharmaceutical Industry Investment Amount: The total planned investment of the project is 501.46 million yuan, and the source of funds is self-raised.
l Special Risk Reminder: The construction period of this project is relatively long. With the continuous advancement of the domestic medical system reform
, the hospital's strict control of drug proportion, sunshine procurement and quantity procurement, secondary bargaining, prescription outflow, etc. continue to deepen, and drug prices show a downward trend. In addition, trade protectionism is on the rise and competition in the international market will become more intense, profitability may be affected and there is a risk that project returns will not meet expectations.
1. Project Investment Overview
According to the company's strategic policy of "strengthening the main business through cooperation and innovation, standardizing science and seeking development", Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical Co., Ltd."), a subsidiary of the company, is based on the development strategy of the company and relevant regulations of national pharmaceutical production, in order to further improve the solid preparation production capacity of Jianfeng Pharmaceutical, it is planned to acquire about 78 mu of land on the north side of the existing factory area of Jianfeng Pharmaceutical in Jinhua Economic Development Zone, set up a new preparation factory area, and build a preparation manufacturing platform that meets the requirements of GMP in Europe and America. The construction of the project with an annual output of 2 billion solid preparations in Jinxi Production Base of Jianfeng Pharmaceutical includes two preparation workshops and supporting storage, quality inspection, public works, etc. After the completion of the preparation workshop 1 to form an annual production capacity of 2 billion pieces of solid preparations, while reserving the preparation workshop 2 for later development.
On August 3, 2018, the fifth meeting of the tenth board of directors of the company reviewed and approved the "Proposal on the Project of 2 billion Solid Preparations per Year in Jinxi Production Base of Jianfeng Pharmaceutical", and agreed to invest in the construction of Jinxi Production Base with an annual output of 2 billion solid preparations.
In accordance with the "Shanghai Stock Exchange Stock Listing Rules", "Articles of Association" and other relevant regulations, this project investment is within the decision-making authority of the company's board of directors and does not need to be submitted to the company's shareholders meeting for approval. Related party transactions do not constitute a major asset reorganization as stipulated in the "Administrative Measures for the Major Asset Reorganization of Listed Companies.
Basic Information of 2. Investment Subject
(I) Investment Subject: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
(II) Enterprise Nature: Other Limited Liability Company
(III) Registered Capital: 198.53 million yuan
(IV) Registered Address: legal Representative of (V) Company
, 2nd Floor, X02 Office Quality Inspection Building, No. 58 Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province: Jiang Xiaomeng
(VI) Scope of Business: Drug Research and Development and Production (Operating with Valid License); Annual recovery: 8 tons of isopropanol, 76 tons of ethanol, 40 tons of toluene, 409 tons of dichloromethane, and 11 tons of ethyl acetate (operating with valid licenses); imported raw and auxiliary materials for production and scientific research; imported machinery and equipment, instruments and spare parts. (Projects subject to approval according to law can only be operated after approval by relevant departments)
(VII) Financial Situation: As of December 31, 2017, Jianfeng Pharmaceutical has total assets of 1,193.4823 million yuan and net assets of 378.2793 million yuan attributable to owners of the parent company. In 2017, it will realize operating income of 1,337.522 million yuan, operating profit of 50.6395 million yuan and net profit of 37.6413 million yuan attributable to owners of the parent company. Basic Information of
3. Investment Project
(I) Project Name: Jianfeng Pharmaceutical Jinxi Production Base Annual Output of 2 billion Pieces of Solid Preparation Project
(II) to Form Production Scale after Completion: Annual Output of 2 billion Pieces of Solid Preparation
(III) Total Building Area: 63352 m2
Total (IV) Investment: the total investment is 501.46 million yuan, of which the investment in fixed assets is 481.98 million yuan and the working capital is 19.48 million yuan.
(V) construction progress: after the conditions are met, the project construction period is 2 years. The main content of the
(VI) project: the annual output of 2 billion pieces of solid preparations in Jinxi production base of Jianfeng pharmaceutical includes two preparation workshops and supporting storage, quality inspection, public works, etc. After the completion of the preparation workshop 1 to form an annual production capacity of 2 billion pieces of solid preparations, while reserving the preparation workshop 2 for later development.
Impact of 4. Investment Project on Listed Companies
Jianfeng Pharmaceutical has rich experience in preparation research and development, production and sales. This project will further improve the construction of generic preparation production base, promote the upgrading of preparation industry and enhance the comprehensive competitiveness of the company's pharmaceutical sector. Under the background of preparation internationalization and continuous improvement of generic drug consistency evaluation, this project takes international generic drugs as the entry point, which is of great significance to improve the equipment level and manufacturing capacity of Jianfeng pharmaceutical preparations, expand the industrial scale, optimize the product structure and participate in international competition, and will have a positive impact on the future development of the company.
Risk Analysis of 5. Investment Project
(I) Market Risk
The construction period of this project is relatively long. With the continuous advancement of domestic medical system reform, hospitals continue to deepen the 120 of # in strict control of drug proportion, sunshine procurement and quantity procurement, secondary bargaining, prescription outflow, etc, drug prices are on a downward trend; in addition, trade protectionism is on the rise and competition in the international market will become more intense, which may affect profitability, and there is a risk that the project revenue will not meet expectations .
(II) Project Construction and Management Technical Risks
Project is still in the preliminary preparation stage, and land acquisition and environmental assessment have not yet been completed. With the adjustment of relevant national industrial policies and urban planning, the project construction There are certain uncertainties in the content, cycle and process. After the project is completed and put into production, there is a possibility that the expected goals may not be achieved in terms of product process improvement and cost control, and there are certain management and technical risks.
(III) Capital Risk
The total investment of this project is relatively large. The project is invested through self-raised funds. There is uncertainty as to whether the funds can be in place on schedule. The fund raising and credit policy changes in the construction process, The smoothness of financing channels will make the company bear certain capital risks.
(IV) Approval Risk
After the project is reviewed and approved by the board of directors, the project construction still needs to go through compliance procedures such as safety assessment and environmental assessment, and is still in the process of approval. Therefore, whether the project can be finally implemented, There is still some uncertainty about the progress after implementation.
6. Reference Document
Resolution of the Fifth Meeting of the Tenth Board of Directors
is hereby announced.
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
August 3, 2018
More information
Teachers and Students of Zhejiang Gongshang University Visit Peak Health
News from our newspaper On the morning of June 9, a group of 18 teachers and students from Zhejiang Gongshang University came to Jianfeng Health for a visit and discussion, and conducted research on the establishment of Zhejiang Gongshang University Food Industrialization Research Institute in Jinhua. The leader of this visit is Professor Song Guanglei from the School of Food and Biological Engineering, Zhejiang Gongshang University. The teachers and students are mainly from the School of Food and Engineering, specializing in food science, food safety, biochemical and biotechnology, focusing on extraction and separation, functional activity and The research of functional food, in addition to the professor of the Department of E-commerce of the School of Management Engineering and E-commerce. Chen Daiyou, general manager of Jianfeng Health, Li Wende, deputy general manager, and relevant personnel from R & D, quality management, administrative personnel and other departments attended the forum. Li Wende introduced the basic situation, technical production level, scientific and technological research and development characteristics of Jianfeng Health Company in the form of PPT, as well as the relevant policies of Jinhua Municipal Government on talent introduction. Chen Daiyou focused on the development vision of Jianfeng Health Technology and the construction of scientific and technological talents, and welcomed graduate students from the Industrial and Commercial University to join the team of Jianfeng Health after graduation. Professor Song Guanglei fully affirmed the software and hardware facilities and humanistic management of Jianfeng Health Company. He said that most of the teachers and students who came to visit this time were professional in line with the industry of Jianfeng Health Company. The two sides could carry out in-depth cooperation in product development, technology upgrading and talent reserve. Fourteen graduate students also introduced their respective situations and study and research directions. After the symposium, the teachers and students visited the health company's testing center, R & D laboratory and plant extraction workshop with great interest.
2020
07-31
Trial operation of large pharmacy micro-mall
The construction of the micro-mall of Jianfeng Pharmacy is basically ready at present. On June 17, Shuangxi and Donglai chain stores took the lead in the trial operation of the micro-mall. At present, online consumption through computers and mobile phones has become a way of life in China. In particular, various software represented by WeChat covers more than 90% of smart phones, and has many functions such as information exchange and online payment. It is a new type of shopping system based on WeChat platform, using mobile Internet technology to realize the integration of online and offline marketing. At present, there are more than 1000 kinds of commodities on the shelves of the micro-mall of Jianfeng pharmacy, mainly OTC commodities of over-the-counter drugs, which are basically synchronized with pharmacies. Customers only need to pay attention to the public number of Jianfeng Pharmacy and enter the micro-mall to collect coupons through the "online drug purchase" on the public number page. They can find the required drugs on the mobile phone to purchase and pay for them. The delivery method can be delivered to the door or the store can pick them up by itself. The purchase of drugs through the micro-mall is not only convenient and fast, but also can reduce the phenomenon of queuing in the store. According to reports, the opening of the micro mall by the big pharmacy is to expand the new service model and provide more and better extended services to the masses. Prior to this, the WeChat public number of the large pharmacy has already made a useful attempt to push health information, and the operation of the micro-mall will further provide users with new channels for seeking medical advice. While further improving the micro-mall system, the large pharmacy will add "online pharmacists" and other service items to provide users with real-time consulting services such as medication guidance, drug purchase recommendation, health care knowledge and so on in the form of voice or text. (Tang Wenshu)
2020
07-31
Spike Health gets patent grants
Recently, Jianfeng Health Technology Company's invention patent "a low-temperature and low-pressure freeze-drying method for notoginseng chewable tablets" won a patent subsidy from Jinhua Science and Technology Bureau in 2017. In order to encourage invention and creation, promote independent innovation, promote the development of patented technology and products, and speed up the transformation of patent achievements, Jinhua Science and Technology Bureau gives invention patent subsidies to enterprises within its jurisdiction every year. Patent subsidies are declared once a year. After authorization, each domestic invention patent can receive a subsidy of 40000 yuan, including 20000 yuan in Jinhua City and 20000 yuan in the district. The invention patent of spike health "a low-temperature and low-pressure freeze-drying method of notoginseng chewable tablets" obtains notoginseng chewable tablets by washing, slicing and other pretreatment of fresh notoginseng main roots, then placing them in a vacuum dryer for vacuum freeze-drying. As the top high and new technology in the field of dehydration products, the whole freeze-drying process is carried out at low temperature, which avoids the quality deterioration reactions such as oxidation of active ingredients, destruction of volatile oil and other heat-sensitive substances in the traditional drying process. It can maximize the retention of various nutrients and active substances of medicinal materials and perfectly reproduce its initial type, color and taste, it has the characteristics of light weight, fast rehydration, convenient consumption and long storage period. The actual effect, appearance and color are basically the same as those of fresh Panax notoginseng. The effective ingredients are about 50% higher than those of products processed by traditional processes such as drying and drying. It is understood that the 2017 Jinhua patent subsidy of 20000 yuan obtained by Jianfeng Health is currently in place, and the application of patent subsidy in Wucheng District is in progress. (Xu Feng)
2020
07-31
Spike Health gets patent grants
Recently, Jianfeng Health Technology Company's invention patent "a low-temperature and low-pressure freeze-drying method for notoginseng chewable tablets" won a patent subsidy from Jinhua Science and Technology Bureau in 2017. In order to encourage invention and creation, promote independent innovation, promote the development of patented technology and products, and speed up the transformation of patent achievements, Jinhua Science and Technology Bureau gives invention patent subsidies to enterprises within its jurisdiction every year. Patent subsidies are declared once a year. After authorization, each domestic invention patent can receive a subsidy of 40000 yuan, including 20000 yuan in Jinhua City and 20000 yuan in the district. The invention patent of spike health "a low-temperature and low-pressure freeze-drying method of notoginseng chewable tablets" obtains notoginseng chewable tablets by washing, slicing and other pretreatment of fresh notoginseng main roots, then placing them in a vacuum dryer for vacuum freeze-drying. As the top high and new technology in the field of dehydration products, the whole freeze-drying process is carried out at low temperature, which avoids the quality deterioration reactions such as oxidation of active ingredients, destruction of volatile oil and other heat-sensitive substances in the traditional drying process. It can maximize the retention of various nutrients and active substances of medicinal materials and perfectly reproduce its initial type, color and taste, it has the characteristics of light weight, fast rehydration, convenient consumption and long storage period. The actual effect, appearance and color are basically the same as those of fresh Panax notoginseng. The effective ingredients are about 50% higher than those of products processed by traditional processes such as drying and drying. It is understood that the 2017 Jinhua patent subsidy of 20000 yuan obtained by Jianfeng Health is currently in place, and the application of patent subsidy in Wucheng District is in progress. (Xu Feng)
2020
07-30
Spike Health gets patent grants
Recently, Jianfeng Health Technology Company's invention patent "a low-temperature and low-pressure freeze-drying method for notoginseng chewable tablets" won a patent subsidy from Jinhua Science and Technology Bureau in 2017. In order to encourage invention and creation, promote independent innovation, promote the development of patented technology and products, and speed up the transformation of patent achievements, Jinhua Science and Technology Bureau gives invention patent subsidies to enterprises within its jurisdiction every year. Patent subsidies are declared once a year. After authorization, each domestic invention patent can receive a subsidy of 40000 yuan, including 20000 yuan in Jinhua City and 20000 yuan in the district. The invention patent of spike health "a low-temperature and low-pressure freeze-drying method of notoginseng chewable tablets" obtains notoginseng chewable tablets by washing, slicing and other pretreatment of fresh notoginseng main roots, then placing them in a vacuum dryer for vacuum freeze-drying. As the top high and new technology in the field of dehydration products, the whole freeze-drying process is carried out at low temperature, which avoids the quality deterioration reactions such as oxidation of active ingredients, destruction of volatile oil and other heat-sensitive substances in the traditional drying process. It can maximize the retention of various nutrients and active substances of medicinal materials and perfectly reproduce its initial type, color and taste, it has the characteristics of light weight, fast rehydration, convenient consumption and long storage period. The actual effect, appearance and color are basically the same as those of fresh Panax notoginseng. The effective ingredients are about 50% higher than those of products processed by traditional processes such as drying and drying. It is understood that the 2017 Jinhua patent subsidy of 20000 yuan obtained by Jianfeng Health is currently in place, and the application of patent subsidy in Wucheng District is in progress. (Xu Feng)
2020
07-31
On May 27, the Party Committee of the Group Company held a branch secretary meeting to comprehensively review and summarize the Party building work of the Company in 2016 and sign the responsibility book for the management of Party building work objectives in 2017. At the meeting, Qin xuping, member of the party Committee of the group company and director of the party-mass work department, made a comprehensive summary of the company's party building work in 2016, put forward the 2017 work plan, and conveyed the "key points of party building work in the city's two new organizations in 2017" issued by the two new working committees of Jinhua municipal party Committee, and the spirit of the speech made by the relevant leaders of the municipal party Committee at the recent meeting of the city's two new working committee, this paper explains the "ten questions" of the two new grass-roots party organizations, the "ten questions" of Party members and some problems that need attention in the process of Party member development. Members of the party committee of the group company, secretaries of grass-roots party committees and branch secretaries expressed their views and conducted extensive exchanges on such topics as how to deepen the "two learning and one doing", further play the role of party organizations in the process of enterprise operation and management, and how to do a good job in organizational construction in 2017. Jiang Xiaomeng, secretary of the party committee and chairman of the group company, on behalf of the party committee of the group, signed the 2017 party building work target management responsibility letter with the heads of the party organizations of various professional companies and directly affiliated enterprises. In his speech at the meeting, Jiang Xiaomeng said that the Politburo meeting of the CPC Central Committee held on the 26th reviewed and approved the "Decision on Amending the Regulations on the Inspection Work of the Communist Party of China" and other reports, which is a major measure to further implement the provisions of the party constitution and strengthen internal party supervision. Specific to the internal party building work of the enterprise, all cadres and party members should earnestly study relevant policies and documents, and earnestly understand the spirit of the central government
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page